Brought to you by 
Earlens gets $87mm via late-stage financing
30 Oct 2018
Executive Summary
Earlens Corp. (developed the first non-surgical hearing device) raised $87mm in its late-stage financing of preferred stock led by KCK, which was joined by other first-time backer Exor Seeds and returning shareholders Lightstone Ventures, CRG Partners, Windham Life Sciences Partners, Arch Healthcare, Relativity Health Fund, New Enterprise Associates, Aisling Capital, Vertex Global Healthcare, MS Pace LP, Cochlear, Mellon Foundation, Baltisches Haus, GDN Holdings, Sightline Healthcare Opportunity, and Far East Ventures. The company will use the funds for ongoing product development and the anticipated commercial rollout next year. Three representatives from KCK will join the board.
Deal Industry
- Medical Devices
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Earlens gets $87mm via late-stage financing
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice